Basel Medical Group Ltd
BMGL
$4.45
$0.040.91%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -0.97% | -43.37% | 0.00% | 11.63% | -0.45% |
| Total Depreciation and Amortization | -0.92% | 0.00% | 0.00% | 11.58% | -0.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.95% | -253.14% | 0.00% | -20.08% | -0.51% |
| Change in Net Operating Assets | -0.97% | 200.35% | 0.00% | -1,615.47% | 0.29% |
| Cash from Operations | -0.97% | 1,555.53% | 0.00% | -90.67% | -0.47% |
| Capital Expenditure | -- | 100.00% | 0.00% | -383.33% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 0.00% | -383.33% | 0.00% |
| Total Debt Issued | 0.00% | -76.19% | 0.00% | 112.36% | 0.00% |
| Total Debt Repaid | 0.00% | 12.51% | 0.00% | -120.61% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -- | -- | 0.00% |
| Cash from Financing | 0.97% | -233.51% | 0.00% | 76.52% | 0.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -0.96% | 470.25% | 0.00% | -33.20% | 0.39% |